【摘要】目的探讨血液透析患者血清金属蛋白酶ADAMTS7 浓度与血管钙化的关系。方法根据患者血清金属蛋白酶ADAMTS7 水平，将73 例维持性血液透析分成高浓度组(n=29 例)、低浓度组(n=44例)，用多部位平片法评估患者血管钙化情况，比较2 组患者临床资料、生化资料及血管钙化情况。结果高浓度组和低浓度组的血管钙化发生率分别是86%(23/29)和57%(25/44)，差异具有显著性(P=0.048)，高浓度组较低浓度组患者透析龄长(72.5±67.8 月vs. 46.7±37.1 月,P =0.040),血钙浓度高(2.50±0.30 mmol/L vs. 2.23±0.23mmol/L,P =0.002)。回归分析提示高浓度血清ADAMTS7 是发生血管钙化的预测因素之一。结论血液透析患者血清金属蛋白酶ADAMTS7 浓度与血管钙化发生有关，可能是其预测因素之一。

【Abstract】Objective To investigate the correlation between plasma metalloproteinase ADAMTS7 and vascular calcification in maintenance hemodialysis (MHD) patients. Methods A total of 73 MHD patients were divided into high ADAMTS7 group (n=29) and low ADAMTS7 group (n=44) according to their plasma
metalloproteinase ADAMTS7 levels. Vascular calcification was evaluated by plain X-ray films of pelvis and hands. Demographic data, clinical features, biochemical parameters, and vascular calcification were then compared between the two groups. Results Vascular calcification was detected in 23 patients in the high ADAMTS7 group (86%) and in 25 patients in the low ADAMTS7 group (57%, P=0.048). Patients with higher ADAMTS7 level had longer dialysis duration (72.5±67.8 months vs. 46.7±37.1 months, P=0.04) and higher plasma calcium (2.50±0.30 mmol/L vs. 2.23±0.23 mmol/L, P=0.002) than those with lower ADAMTS7 level. Regression analysis showed that higher plasma ADAMTS7 level was one of the vascular calcification risk factors in MHD patients. Conclusion Plasma metalloproteinase ADAMTS7 level is probably a risk factor of vascular calcification in MHD patients.